# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹5,365.6 Cr** FY '26 (+20%) * **Gross Margin:** **65%** FY '26 (+355 bps) · **65.7%** Q4 FY '26 (+233 bps) * **EBITDA:** **₹1,185.1 Cr** FY '26 (+25%) · **₹352.1 Cr** Q4 FY '26 (+40%) * **EBITDA Margin:** **22.1%** FY '26 · **23.9%** Q4 FY '26 * **PAT:** **₹595 Cr** FY '26 (+19%) · **₹201.6 Cr** Q4 FY '26 (+33%) * **Leverage & Returns:** **0.34x** Net Debt/EBITDA · **17.6%** ROCE * **Cash Flow & Capex:** **₹793.3 Cr** OCF FY '26 · **₹554.7 Cr** Capex FY '26 ## B. Revenue & Profitability Trends * **Consistent Growth Trajectory:** Achieved a significant revenue milestone supported by six consecutive quarters of sequential growth and operational stability in API and finished dosage segments. * **Structural Margin Expansion:** Long-term gross margin transformation (from **50% in FY '22**) driven by a strategic shift toward complex generics and high-value CDMO contributions. * **CDMO Momentum:** The peptide CDMO segment reached a critical turning point, delivering its first quarter of positive EBITDA and doubling revenue sequentially from **INR 33 Cr to INR 70 Cr**. * **Operational Resilience:** Robust bottom-line growth maintained despite headwinds from elevated logistics costs, remediation expenses, and a **INR 44.5 Cr** loss from the newly acquired Ascelis platform. ## C. Balance Sheet & Liquidity * **Deleveraging Success:** Substantial reduction in net debt facilitated by a **INR 665.6 Cr** equity infusion and strong internal accruals. * **Capital Allocation:** Funding from promoters and QIP is earmarked for organic growth, R&D, and potential inorganic opportunities to strengthen market positioning. * **Working Capital Management:** Despite cost escalations and a planned buildup for new launches, management aims to hold the working capital-to-sales ratio steady at **33%**. ## D. Future Capex & Outlook * **Strategic Infrastructure Investment:** Planned outlay of approximately **INR 600 Cr** for the next fiscal, targeting a new API facility and IT infrastructure. --- # 2. Product & Segment Performance ## A. Key Figures * **Finished Dosage Revenue Mix:** **74%** of total revenue * **European Market Growth:** **81%** YoY (+49% ex-Senn) · **15%** of total revenue * **API Segment Growth:** **33%** for the quarter ## B. Finished Dosage & API Core * **Geographic Momentum:** Robust top-line expansion driven by broad-based formulation demand in North America and Europe, enhancing business sustainability. * **API Diversification:** Significant segment growth fueled by new product launches and a strategic shift toward external sales of internally developed APIs. ## C. Peptide CDMO Platform (Ascelis & Senn) * **Strategic "Blue Ocean" Expansion:** Management is investing **INR 200 Cr** into the platform, targeting high-potential segments including GLP-1s, peptide drug conjugates, and oligonucleotides. * **Commercial Transition:** Growth is shifting from a low base to an execution-led model, with one major project reaching stable commercial supply and others in clinical stages. * **Cosmetic Traction:** Meaningful revenue uplift driven by "TFA-free" peptides, which have seen increased project volumes and customer attention over the last two quarters. * **Infrastructure Development:** Plans are underway for a large-scale manufacturing facility in India to service a diverse client base of big pharma and virtual biotechs. ## D. Controlled Substance Portfolio * **Quota & Pipeline Security:** Secured CY '25 DEA quotas for Lisdexamfetamine; management expects sufficient allocations through FY '27 to meet internal sales targets. * **ADHD Portfolio Scaling:** Global expansion is underway with **1 to 2 new launches** planned annually; API revenue is imminent, while finished dosage revenue is expected within **2 years**. * **Diversified Growth:** Market leadership in the ADHD space is being driven by a multi-product strategy rather than reliance on a single molecule. --- # 3. Manufacturing & Capacity ## A. Key Figures * **B. S. Market Ranking:** **27th** by sales value (up from 74th in FY '21) · **4th** in controlled substances * **DCDA Project Capex:** **₹200 Cr** estimated cost for commercial plant ## B. Facility Utilization & Global Strategy * **Capacity Ramp-up:** Current utilization remains healthy, with new Indian intermediate and Zurich facilities projected to reach full capacity by **H2 FY'26**. * **C. S. Operational Milestone:** The Virginia (GPI) facility achieved its targeted operating potential, driving a significant leap in U.S. generic market positioning. * **Operational Resilience:** Management is actively executing cross-site product transfers to mitigate supply chain risks and ensure continuity. ## C. Peptide Value Chain Expansion * **Phased Infrastructure Upgrades:** Capital expenditure is focused on the peptide API value chain, starting with Zurich capacity followed by a brownfield intermediate facility in India. * **Long-term Pipeline:** Planning is underway for a dedicated India-based peptide API facility, slated to commence construction approximately **one year** after initial phase completion. * **Executive Alignment:** Infrastructure upgrades in Zurich are being paired with long-term incentive programs for key executives to ensure project delivery. ## D. Backward Integration & Competitive Moat * **DCDA Project Advancement:** Pilot stage for Dicyandiamide is finalizing; equipment orders for the commercial plant are expected within **2 to 2.5 months**. * **Strategic Decoupling from China:** The DCDA initiative positions the company as the sole manufacturer outside of China, providing a critical hedge against aggressive Chinese pricing. * **Intermediate Self-Sufficiency:** The new Indian facility will produce **protected amino acid derivatives**, serving internal peptide programs while capturing external market demand. --- # 4. Technology & Innovation ## A. Key Figures * **R&D Expenditure:** **₹285.3 Cr** Total FY26 (5.3% of sales) * **Regulatory Filings:** **6** US ANDAs · **3** EU dossiers · **1** Canadian dossier · **15** Regional filings * **DMF Submissions:** **6** US DMFs · **10** Other regional DMFs ## B. R&D Pipeline & Strategic Focus * **High-Barrier Specialization:** R&D investment is concentrated on complex generics, specifically targeting **CII/ADHD, oncology, and MUPS** to secure differentiated market positioning. * **Next-Gen Modalities:** While current efforts prioritize peptides, the company is actively evaluating a roadmap into **PDCs, ADCs, and oligonucleotides**, currently in the planning phase. * **Peptide Commercialization:** The **Peptide Center of Excellence** is now fully operational, engaging in live projects including **TFA-free cosmetics** and pharmaceutical sampling. ## C. Complex Product Shift * **TAM Expansion:** The portfolio is pivoting toward controlled substances and oncology, targeting a combined addressable market of **$41 billion**. * **Value Creation:** Strategy is accelerating toward complex products to facilitate **first-to-file (FTF)** opportunities and enhance long-term competitive moats. ## D. Digital Quality Systems * **Compliance Infrastructure:** Systematic strengthening of quality systems via **digital infrastructure**, including electronic logbooks and document control, to ensure global audit readiness. * **Operational Effectiveness:** Implementation of **Manufacturing Execution Systems (MES)** and automated calibration management to streamline manufacturing site compliance. --- # 5. M&A & Strategic Initiatives ## A. Key Figures * Peptide CDMO Revenue: ₹1,593 Cr FY26 Contribution * **Revenue Mix:** **3%** of Group Total Turnover * **Profitability Status:** **EBITDA Positive** within three quarters post-acquisition ## B. Senn Chemicals Integration * **Strategic Entry:** Acquisition successfully established a foothold in the high-growth peptide CDMO segment, serving as a long-term growth engine. * **Operational Turnaround:** The Zurich facility achieved positive EBITDA despite higher operating overheads from increased manpower and extra shifts for a major client program. * **Execution Model:** Integration provides a validated "two-continent" execution model, offering high-quality customer bases proof of concept across both India and Europe. * **Growth Pillar:** Management views the peptide business as a primary driver of future group performance, though specific order book and margin profiles remain internal. ## C. Portfolio Repositioning * **Strategic Reset:** FY26 served as a deliberate period of operational and regulatory correction to stabilize the business for sustainable, value-led growth. * **Execution Focus:** Efforts were concentrated on strengthening execution and repositioning the portfolio to withstand external cost pressures. ## D. Customer Partnership Model * **Demand-Linked Expansion:** CDMO capacity deployment is strictly aligned with customer program progression, providing investment optionality while avoiding speculative capex. * **Risk Mitigation:** The company maintains a broad-based participation strategy to ensure the customer base is not overly concentrated during this scaling phase. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Remediation Capex:** **>₹50 Cr** Cumulative FY26 spend * **Audit Track Record:** **108** Customer audits passed · **13** Regulatory audits passed (FY26) * **Regulatory Outcomes:** **VAI Status** GLS Genome Valley · **Zero Observations** GCH Virginia · **4 Observations** Chantilly GPI ## B. FDA Remediation Status * **Gagillapur Readiness:** Material progress achieved on post-warning letter remediation, with cleaning validations completed across all dosage blocks and final action responses submitted. * **Audit Timing:** Management has officially notified the FDA of "anytime audit" readiness as of March 2026, though the specific reinspection timeline remains outside company control. * **Cost Outlook:** Following significant investment in compliance during the current fiscal year, remediation-related expenses are projected to be substantially lower entering FY 2027. ## C. Inspection & Compliance * **Global Compliance Momentum:** Strong confidence in quality systems underpinned by successful ANVISA and customer audits with no critical findings. * **Operational Constraints:** Management identifies regulatory timelines and execution quality as the primary bottlenecks for scaling operations over the next **2-3 years**. * **Procedural Observations:** Recent inspection at the Chantilly facility resulted in minor procedural Form 483s; notably, no data integrity issues were flagged. ## D. Input Cost Inflation & Logistics * **Margin Headwinds:** Rising raw material, packaging, and freight costs have led management to retract previous gross margin guidance of **64% to 65%**. * **Pricing Strategy:** Despite upward pressure on inputs, API prices remained stagnant; the company is now actively seeking price pass-throughs to defend profitability. * **Supply Chain Resilience:** Current inventory buffers are expected to provide a short-term hedge against logistics disruptions in West Asia and associated cost spikes. --- # 7. Guidance & Outlook ## A. Key Figures * **Pending Approvals:** **9** U.S. applications awaiting Gagillapur site clearance * **Near-term Pipeline:** **2** tentative approvals (litigation pending) · **1-2** generic launches · **1-2** potential first-to-file (FTF) launches ## B. FY27 Strategic Priorities * **Operational Foundation:** FY26 concluded with material gains in compliance and portfolio quality, setting the stage for disciplined capital allocation and complex product scaling in the coming year. * **C. S. Market Readiness:** Strategic focus remains on maintaining FDA readiness at the Gagillapur facility to unlock the pending application pipeline. ## C. Margin & Debt Targets * **Subsidiary Turnaround:** Management implemented a leaner structure at Senn and expects the unit to achieve annual PAT-positive performance in the next fiscal year. * **Peptide Profitability:** Following recent EBITDA breakeven, Ascelis Peptides is targeted to reach sustainable annual EBITDA and PAT positivity starting next fiscal, despite potential quarterly volatility from milestone timings. * **Balance Sheet Outlook:** Net debt levels are under evaluation, sensitive to ongoing CAPEX and potential working capital spikes driven by **geopolitical uncertainties**. ## D. Long-term Growth Drivers * **High-Value Pipeline:** Growth strategy pivots toward targeted FTF and NCE-1 filings, with an emphasis on "Day 1" market entry to maximize value capture. * **Geographic Diversification:** Long-term roadmap includes a phased entry into the European market, beginning with API filings followed by finished dosages.